Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives

Abstract

CD4+CD25+Foxp3+ regulatory T cells (Tregs) are functionally distinct subsets of mature T cells with broad suppressive activity and have been shown to play an important role in the establishment of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT). Tregs exhibit an activated phenotype from the stage of emigration from the thymus and maintain continuous proliferation in the periphery. The distinctive feature in homeostasis enables Tregs to respond sensitively to small environmental changes and exert necessary and sufficient immune suppression; however, on the other hand, it also predisposes Tregs to be susceptible to apoptosis in the inflammatory condition post-transplant. Our studies have attempted to define the intrinsic and extrinsic factors affecting Treg homeostasis from the acute to chronic phases after allogeneic HSCT. We have found that altered cytokine environment in the prolonged post-HSCT lymphopenia or peri-transplant use of immune checkpoint inhibitors could hamper Treg reconstitution, leading to refractory graft-versus-host disease. Using murine models and clinical trials, we have also demonstrated that proper intervention with low-dose interleukin-2 or post-transplant cyclophosphamide could restore Treg homeostasis and further amplify the suppressive function after HSCT. The purpose of this review is to reconsider the distinctive characteristics of post-transplant Treg homeostasis and discuss how to harness Treg homeostasis to optimize posttransplant immunity for developing a safe and efficient therapeutic strategy.

Eras of designer Tregs: Harnessing synthetic biology for immune suppression

“…Another drug, cyclophosphamide, which is used to prevent acute GVHD after hematopoietic stem cell transplant and condition people for CAR T cell therapy, may also have beneficial effects on Tregs. Cyclophosphamide has shown to impair alloreactive T‐cell function, but it appears to spare Tregs, allowing them to proliferate and reconstitute before other T cells, possibly contributing to early establishment of tolerance 176 . Considering the biological mechanisms of action and targets of immunosuppressive drugs may therefore be helpful when choosing induction therapies to combine with Treg therapy.…”

New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies

“…This approach proved very effective in reducing the risk of GvHD related to haplo-HSCT by favoring Treg-cell reconstitution and restoring the Treg-cell/Tconv-cell ratio. 92 Mesenchymal stem cells. Mesenchymal stem cells represent a subset of cells endowed with immunosuppressive properties, capable of inducing Treg cells and in promoting Tconv-cell differentiation toward a T H 2 phenotype in vitro and in vivo in several preclinical models.…”

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

“…The absolute or relative depletion of Treg cells, especially during tumor infiltration, is associated with the (re)induction of protective anti-cancer immunity, indicating a shift from silent or ineffective immune responses to open or effective ones ( Ikegawa and Matsuoka, 2021 ; Nishikawa and Koyama, 2021 ). Previous studies on CTX-induced Treg cell depletion have obtained favorable results, confirming that CTX can mediate multiple mechanisms to selectively deplete Treg cells and further improve the effectiveness of immunotherapy by increasing the activation of autoreactive T cells ( Laheurte et al, 2020 ).…”